The latest news about CBD are here:
- It has been found in a recent study that dogs with osteoarthritis can benefit from CBD treatment.
- Drug laws are amended by South Africa to allow from Some non-prescribed CBD products
- A plan regarding the CBD and marijuana research with direction from the FDA is being analyzed by the White House
Table Of Contents
- Study Finds CBD Treatment Can Benefit The Arthritic Dogs
- Some CBD Products Are Removed Permanently From The Narcotics Scheduling By South Africa
- Research Regarding CBD & Marijuana Is Under Review At The White House
Study Finds CBD Treatment Can Benefit The Arthritic Dogs
It has been found in a recent study that CBD can help in the treatment of arthritis in dogs, and may certify the future analysis of CBD for use in human arthritis treatment.
In this study, nine out of 10 dogs with osteoarthritis showed improvement after treatment with CBD. This study was carried out at Baylor College of Medicine in a partnership with Medterra CBD, and published in the journal PAIN.
Researchers found that there was less production in inflammatory molecules as well as immune cells linked to arthritis in the studied dogs. It was also determined that administration of the CBD via liposome capsules produced faster and effective results.
In a statement, Dr. Matthew Halpert, a part of the research faculty in the Department of Pathology and Immunology at Baylor said that they had studies dogs as evidence from different experiments shows that spontaneous models of arthritis, specifically in domesticated canine models, are more useful for evaluating the arthritis pain treatments in human than other human models. The biological aspects of arthritis in dogs very similar to those of the human condition.”
CBD oil from Medterra was also found to be safe by Dr. Halpert.
“No alternation was found in the blood markers measured by us, suggesting that, the treatment seems to be safe under the conditions of our study.”
Some CBD products Are Removed Permanently From Narcotics Scheduling By South Africa
An amendment has been made by South Africa in its drug law to allow some CBD products to be accessible over the counter. A permanent last year’s amendment was made by the ruling to the Medicines and Related Substances Act of 1965.
Certain CBD medicines and full-spectrum cannabis-derived products are removed by the ruling from medical controls.
Aaron Mostoaledi, the Health Minister, initiated the move in last year’s amendment, which permits these products for non-serious health conditions with a daily dose of 20mg of CBD, or 600mg per pack at maximum. Formerly, a prescription was required for these products.
Restrictions are also removed from the chewable products derived from raw biomass with CBD o.0075% or less.
Research Regarding CBD & Marijuana Is Under Review At The White House
With the guidance from FDA, a federal plan regarding marijuana and CBD research has been put before the White House
Set before the White House Office of Management and Budget (OMB), little information is present about the document entitled: “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research,”
Nonetheless, In a statement, FDA said that CBD and cannabis companies might be allowed eventually to trade their products like food or items dietary supplements.
FDA said ” we acknowledge the people interest in trading and accessing the CBD for diverse products. We are working on a plan for providing extra guidance, and have made considerable development. Many questions regarding safety, science, effectiveness, and quality of the CBD products need to be explored and we have to do it with due attention.”
The statement continued that the FDA continued to investigate different pathways for different kinds of CBD products to be marketed legally as a part of their work. Obtaining and investigating information to answer the exceptional questions related to the CBD products was an important component of that study that would inform their consideration of potential regulatory frameworks for CBD while maintaining the FDA’s precise public health standards.
Those in the CBD and cannabis industries enthusiastically waiting to see whether the FDA will wait for this guidance to be finalized before the issuance of final rules regarding the marketing of CBD and cannabis products.
The comment period for the people to issue input about the safety and efficacy of CBD has also been extended by the FDA
